Back to search
FDAFDA · Food and drugs·Recall number D-0819-2018

Amlodipine and Benazapril HCL Capsules, USP, 5 mg/10 mg, 100 count bottles, Mylan Pharmaceuticals, Inc., Morgantown, WV --- NDC 0378-6896-01

Published May 23, 2018 · Recall initiated: April 24, 2018

Summary

FDA records drug Class II recall D-0819-2018, published May 23, 2018 and initiated April 24, 2018. Recalling firm: Mylan Pharmaceuticals Inc.; Status: Terminated; Reported quantity: 25,488 bottles; Lot: Lot Numbers# 3083005, 3083006, 3086121, and 3086122, exp Jan 2019. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

cGMP Deviations; cleaning process for equipment used to manufacture the specified batches was not followed according to procedure

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Mylan Pharmaceuticals Inc.
Distributor
Product was distributed throughout United States
Lot
Lot Numbers# 3083005, 3083006, 3086121, and 3086122, exp Jan 2019
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Amlodipine and Benazapril HCL Capsules, USP, 5 mg/10 mg, 100 count bottles, Mylan Pharmaceuticals, Inc., Morgantown, WV --- NDC 0378-6896-01 recalled?

Yes. FDA published recall D-0819-2018 on May 23, 2018. Reported hazard: cGMP Deviations; cleaning process for equipment used to manufacture the specified batches was not followed according to procedure

What should I do if I have this product?

Voluntary: Firm initiated · Letter